According to a newly published market research report by 24LifeSciences, global Hepatocellular Carcinoma Drugs market was valued at USD 2.1 billion in 2024 and is projected to reach USD 3.9 billion by 2031, growing at a compound annual growth rate (CAGR) of 8.3% during the forecast period 20252031. Hepatocellular Carcinoma (HCC), the most common primary liver cancer accounting for 90% of...